Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Rasonque Prior Auth Coverage | OpenPaye…
    Ask Trek AI about this page
    ModifiedQualChoicePolicy CP.PHAR.794

    Daraxonrasib (Rasonque) coverage for metastatic pancreatic adenocarcinoma

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.794 alerts

    Get alerted when Policy CP.PHAR.794 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Rasonque (daraxonrasib) for QualChoice commercial, HIM/ICHRA, and Medicaid members, primarily for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or are not candidates for multiagent systemic therapy.

    Policy Summary
    PayerQualChoice
    PolicyDaraxonrasib (Rasonque) coverage for metastatic pancreatic adenocarcinoma
    Policy CodePolicy CP.PHAR.794
    Change TypeModified
    Effective DateAug 26, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionSubmit clinical documentation demonstrating that all applicable initial or continuation criteria for Rasonque are met.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was updated after FDA approval to use the diagnosis term pancreatic adenocarcinoma, permit an exception to prior therapy when the provider attests that the member is not a candidate for multiagent systemic therapy, remove prior ECOG performance-status and central-nervous-system-metastasis requirements, and update dosing.

    Adults with metastatic pancreatic adenocarcinomaFDA-approved population
    150–300 mg/dayAuthorized daily dose
    ≤2 tablets/dayMaximum quantity

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Approval duration
    ≥30 daysContinuation threshold

    Coverage Criteria

    Initial therapy — metastatic pancreatic adenocarcinoma

    Covered when all pancreatic adenocarcinoma initial-approval criteria are met.

    Initial pancreatic adenocarcinoma approval

    • Diagnosis and prescriber: Diagnosis of pancreatic adenocarcinoma; prescribed by or in consultation with an oncologist; age is at least 18 years; and disease is metastatic.Age ≥18 years
    • Prior therapy or inability to receive multiagent therapy

      • Qualifying prior therapy: Disease progression after one previous line of a fluoropyrimidine- or gemcitabine-based therapy for metastatic disease, or after neoadjuvant or adjuvant therapy when metastatic disease was diagnosed less than 6 months after the last dose of that therapy.One previous line; or metastatic disease diagnosed <6 months after the last dose of qualifying neoadjuvant/adjuvant therapy

        See Appendix B therapeutic alternatives.

      • Multiagent therapy exception: Provider attestation that the member is not a candidate for multiagent systemic therapy.
    • Mutation and prior RAS therapy requirements: If an actionable genetic mutation other than the RAS mutation has been identified, the member has received FDA-approved or NCCN guideline-recommended targeted therapy; and the member has not previously received RAS-targeted therapy, such as Lumakras or Krazati.

      See Appendix D for examples of actionable mutations and targeted therapies.

    • Dose and quantity

      • Standard regimen: Dose is at least 150 mg per day, dose does not exceed 300 mg per day, and quantity does not exceed 2 tablets per day.150–300 mg/day; ≤2 tablets/day
      • Evidence-supported alternative regimen: Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.

        The prescribed regimen must be FDA-approved or recommended by NCCN.

    Continuation therapy — metastatic pancreatic adenocarcinoma

    Covered continuation therapy when all pancreatic adenocarcinoma continuation criteria are met.

    Continued pancreatic adenocarcinoma therapy

    • Current treatment and response: Member is currently receiving the medication through the benefit or has documented current use for a covered indication for at least 30 days, and is responding positively to therapy.≥30 days if applicable
    • Dose increase requirements

      • Standard increased regimen: New dose is at least 150 mg per day, new dose does not exceed 300 mg per day, and new quantity does not exceed 2 tablets per day.150–300 mg/day; ≤2 tablets/day
      • Evidence-supported increased regimen:

    Other diagnoses and indications

    Other diagnoses or indications must meet one of the following pathways.

    Other diagnoses or indications

    • Recent label change

      • Formulary or PDL status

        • Formulary or PDL drug: For a drug on the formulary or PDL, refer to the no-coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
        • Non-formulary or non-PDL drug: For a drug not on the formulary or PDL, refer to the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.
    • Other unlisted use: The requested use, such as a diagnosis, age, or dosing regimen, is not specifically listed under the non-authorized-indications section, and the recent-label-change pathway does not apply; refer to the applicable off-label-use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.

    Non-FDA-approved indications that are not addressed in this policy are not authorized unless sufficient documentation of efficacy and safety supports coverage under the applicable off-label-use policy—CP.CPA.09 for commercial members, HIM.PA.154 for health insurance marketplace/ICHRA members, or CP.PMN.53 for Medicaid members—or under the applicable evidence-of-coverage documents.

    Provider Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. The provider must submit documentation demonstrating that the member meets all applicable approval criteria for Rasonque (daraxonrasib).

    Documentation Required

    Clinical Documentation Required

    Submit supporting clinical documentation, such as office chart notes, laboratory results, and other relevant clinical information, to establish that the member meets the policy criteria.

    • Office chart notes
    • Laboratory results
    • Other supporting clinical information
    Documentation Required

    Background

    Daraxonrasib (Rasonque) is an inhibitor of the RAS GTPase family. The FDA-approved indication covered by this policy is for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Coverage review considers prior treatment, management of actionable mutations, prior RAS-targeted therapy, and the requested dosing regimen.

    Definitions

    Definitions
    AbbreviationFDA
    Full definitionFood and Drug Administration
    Definitions
    AbbreviationNCCN
    Full definitionNational Comprehensive Cancer Network

    Initial Therapy Criteria

    Initial therapy

    Initial coverage is available for pancreatic adenocarcinoma when all listed criteria are met.

    • Diagnosis and prescriber: Diagnosis of pancreatic adenocarcinoma; prescribed by or in consultation with an oncologist; age is at least 18 years; and disease is metastatic.Age ≥18 years
    • Prior therapy or inability to receive multiagent therapy

      • Qualifying prior therapy: Disease progression after one previous line of a fluoropyrimidine- or gemcitabine-based therapy for metastatic disease, or after neoadjuvant or adjuvant therapy when metastatic disease was diagnosed less than 6 months after the last dose of that therapy.One previous line; or metastatic disease diagnosed <6 months after the last dose of qualifying neoadjuvant/adjuvant therapy

    Continuation Criteria

    Continued therapy

    Continuation is covered when all criteria are met.

    Continuation therapy

    • Current treatment and response: Member is currently receiving the medication through the benefit or has documented current use for a covered indication for at least 30 days, and is responding positively to therapy.≥30 days if applicable
    • Dose increase requirements

      • Standard increased regimen: New dose is at least 150 mg per day, new dose does not exceed 300 mg per day, and new quantity does not exceed 2 tablets per day.150–300 mg/day; ≤2 tablets/day

    Step Therapy

    StepQualifying prior therapyApplicable exception
    1Disease progression after one previous line of fluoropyrimidine- or gemcitabine-based therapy for metastatic disease. Examples include FOLFIRINOX, modified FOLFIRINOX, NALIRIFOX, OFF, CAPEOX, capecitabine/gemcitabine, gemcitabine monotherapy, erlotinib plus gemcitabine, and other listed gemcitabine-based regimens.Neoadjuvant or adjuvant therapy qualifies when metastatic disease was diagnosed less than 6 months after the last dose of that therapy. The prior-therapy requirement may also be waived when the provider attests that the member is not a candidate for multiagent systemic therapy.

    Quantity Limits

    Quantity Limits
    Minimum daily dose150 mg/day
    Maximum daily dose300 mg/day
    Maximum quantity2 tablets/day
    Policy Summary
    PayerQualChoice
    PolicyDaraxonrasib (Rasonque) coverage for metastatic pancreatic adenocarcinoma
    Policy CodePolicy CP.PHAR.794
    Change TypeModified
    Effective DateAug 26, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionSubmit clinical documentation demonstrating that all applicable initial or continuation criteria for Rasonque are met.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep TherapyQuantity Limits
    New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.

    The prescribed regimen must be FDA-approved or recommended by NCCN.

    Initial Approval Documentation

    For initial approval of pancreatic adenocarcinoma, documentation must establish all applicable requirements:

    • Diagnosis of pancreatic adenocarcinoma.
    • Prescription by or consultation with an oncologist.
    • Member is at least 18 years old.
    • Metastatic disease.
    • Disease progression after one previous line of fluoropyrimidine- or gemcitabine-based therapy for metastatic disease, or after neoadjuvant/adjuvant therapy when metastatic disease was diagnosed less than 6 months after the last dose; alternatively, provider attestation that the member is not a candidate for multiagent systemic therapy.
    • If an actionable genetic mutation other than the RAS mutation has been identified, prior treatment with FDA-approved or NCCN guideline-recommended targeted therapy.
    • No prior RAS-targeted therapy, such as Lumakras or Krazati.
    • The prescribed regimen is FDA-approved or recommended by NCCN, and the dose and quantity meet the policy limits unless supported as an off-label regimen under the applicable evidence exception.
    Documentation Required

    Evidence for Off-Label Dosing

    For an off-label regimen or dose, the prescriber must submit supporting evidence showing that the requested dose is supported by applicable practice guidelines or peer-reviewed literature for the relevant use.

    • Initial requests: submit guideline or literature support when the dose is not within the standard policy limits of at least 150 mg/day, no more than 300 mg/day, and no more than 2 tablets/day.
    • Continuation dose-increase requests: submit guideline or literature support for the new off-label dose when it does not meet the standard limits of at least 150 mg/day, no more than 300 mg/day, and no more than 2 tablets/day.
    • The prescribed regimen must otherwise be FDA-approved or recommended by NCCN unless the applicable off-label evidence supports the requested use.
    Denial Risk

    Failure to Meet Initial Approval Criteria

    Initial approval will be denied when the member does not meet all applicable initial approval criteria or when the provider does not submit sufficient documentation to demonstrate that the criteria are met.

    • The diagnosis, age, metastatic disease, oncology prescriber or consultation, prior-therapy or multiagent-therapy exception, actionable-mutation treatment, and prior RAS-targeted-therapy requirements are not satisfied.
    • The requested dose or quantity exceeds policy limits and no qualifying guideline or peer-reviewed literature support is submitted for the off-label regimen or dose.
    • The prescribed regimen is not FDA-approved or recommended by NCCN and is not supported by the applicable off-label evidence exception.
    Denial Risk

    Failure to Meet Continuation Criteria

    Continuation approval will be denied when the member does not meet all continuation criteria for the covered indication.

    • The member is not currently receiving Rasonque through the Centene benefit, or documentation does not support current treatment for a covered indication for at least 30 days.
    • The member is not responding positively to therapy.
    • For a dose increase, the new dose or quantity exceeds 150 mg/day, 300 mg/day, or 2 tablets/day, as applicable, and no qualifying guideline or peer-reviewed literature support is submitted for the off-label dose.
    • The prescribed regimen is not FDA-approved or recommended by NCCN and is not supported by the applicable off-label evidence exception.
    Denial Risk

    Unaddressed Non-FDA-Approved Indications

    Coverage is not authorized for non-FDA-approved indications that are not addressed in this policy, unless sufficient documentation of efficacy and safety is submitted under the applicable off-label use policy or evidence of coverage documents.

    • Commercial: CP.CPA.09
    • Health insurance marketplace/ICHRA: HIM.PA.154
    • Medicaid: CP.PMN.53
    Multiagent therapy exception: Provider attestation that the member is not a candidate for multiagent systemic therapy.
  1. Mutation and prior RAS therapy requirements: If an actionable genetic mutation other than the RAS mutation has been identified, the member has received FDA-approved or NCCN guideline-recommended targeted therapy; and the member has not previously received RAS-targeted therapy, such as Lumakras or Krazati.
  2. Dose and quantity

    • Standard regimen: Dose is at least 150 mg per day, dose does not exceed 300 mg per day, and quantity does not exceed 2 tablets per day.150–300 mg/day; ≤2 tablets/day
    • Evidence-supported alternative regimen: Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.

      The prescribed regimen must be FDA-approved or recommended by NCCN.

  3. Evidence-supported increased regimen: New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.